Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicus’ SKNJCT-003 Shows Positive Interim Data in Basal Cell Carcinoma
Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.
Product Name : D-MNA
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicus Pharma Submits Phase 2 SKNJCT-004 Design for UAE BCC Treatment
Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.
Product Name : D-MNA
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicus Updates SKNJCT-003 Phase 2 Study for Nodular Basal Cell Carcinoma
Details : D-MNA (doxorubicin) is a dissolvable transdermal patch featuring cellulose-based microneedle arrays loaded with doxorubicin. It is being evaluated for the treatment of nodular basal cell carcinoma.
Product Name : D-MNA
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Swanielle Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Medicus Pharma Expands Phase 2 Study Collaboration in Asia Pacific
Details : The collaboration aims to explore expansion of Phase 2 clinical study evaluating D-MNA, microneedle arrays containing doxorubicin for treatment of Basal Cell Carcinoma in the Asia-pacific region.
Product Name : D-MNA
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Swanielle Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Maxim Group LLC
Deal Size : $4.0 million
Deal Type : Public Offering
Medicus Pharma Raises $4.0M Through Initial Public Offering in the United States
Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.
Product Name : D-MNA
Product Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2024
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Maxim Group LLC
Deal Size : $4.0 million
Deal Type : Public Offering
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Maxim Group LLC
Deal Size : $4.0 million
Deal Type : Public Offering
Medicus Pharma Raises $4.0M in U.S. Initial Public Offering for Pipeline Growth
Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.
Product Name : D-MNA
Product Type : Small molecule
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Maxim Group LLC
Deal Size : $4.0 million
Deal Type : Public Offering